4TZ.F ORIC PHARMAC.INC.DL-0001
- Market cap
- EUR 818M
- P/E
- -
- P/B
- 2.43x
- ROE
- -40.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4TZ.F undervalued?
Graham numberThe Graham number of ORIC PHARMAC.INC.DL-0001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ORIC PHARMAC.INC.DL-0001 fundamental analysis
No fundamental analysis for ORIC PHARMAC.INC.DL-0001 yet.
ORIC PHARMAC.INC.DL-0001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ORIC PHARMAC.INC.DL-0001
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth fact…
Full company profileORIC PHARMAC.INC.DL-0001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ORIC PHARMAC.INC.DL-0001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -78.9M | -86.8M | -111M | -143M | -143M | -170M |
| EBITDA | - | -85.8M | -110M | -142M | -142M | -169M |
| Net Income | -78.7M | -89.1M | -101M | -128M | -129M | -155M |
| EPS | -2.00 | -1.98 | -1.84 | -1.80 | -1.31 | -1.49 |
| Balance Sheet | ||||||
| Total Assets | 299M | 247M | 252M | 274M | 409M | 405M |
| Total Liabilities | 25.7M | 24.8M | 27.9M | 31.0M | 24.5M | 23.4M |
| Shareholders' Equity | 273M | 222M | 224M | 243M | 384M | 381M |
| Cash & Short-term Investments | 226M | 66.8M | 23.4M | 59.4M | 45.7M | 37.5M |
| Cash Flow | ||||||
| Operating Cash Flow | -59.5M | -75.1M | -85.7M | -113M | -111M | -128M |
| Capital Expenditure | 939K | 2.08M | 849K | 1.19M | 712K | 716K |
| Free Cash Flow | -60.5M | -77.2M | -86.5M | -114M | -112M | -129M |
| Ratios | ||||||
| ROE | -28.8% | -40.1% | -44.9% | -52.6% | -33.7% | -40.5% |
| ROA | -26.4% | -36.1% | -40.0% | -46.6% | -31.7% | -38.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
ORIC PHARMAC.INC.DL-0001 dividends
ORIC PHARMAC.INC.DL-0001 has not paid dividends in the last 5 fiscal years.
Who owns ORIC PHARMAC.INC.DL-0001
- Insiders 1.59%
- Institutions 98.41%
- Public & others 0.00%
- Shares outstanding 104M
- Free float 88.7M
ORIC PHARMAC.INC.DL-0001 company profile
- Company name
- ORIC PHARMAC.INC.DL-0001
- Ticker
- 4TZ.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 111
- Fiscal year end
- December
- Address
- 240 E. Grand Ave, South San Francisco, CA, United States, 94080
- Phone
- 650 388 5600
- Website
- oricpharma.com
About ORIC PHARMAC.INC.DL-0001
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
ORIC PHARMAC.INC.DL-0001 management
10- Dr. Richard A. Heyman Ph.D.Founder, Independent Chairman & Member of Scientific Advisory Board · born 1957
- Dr. Jacob M. Chacko M.B.A., M.D.President, CEO & Director · born 1979
- Mr. Dominic G. Piscitelli CPA, M.B.A.Chief Financial Officer · born 1975
- Dr. Pratik S. Multani M.D., M.S.Chief Medical Officer · born 1967
- Dr. Charles L. Sawyers B.A., M.D., Ph.D.Founder & Member of Scientific Advisory Board · born 1959
- Dr. Scott W. Lowe Ph.D.Founder & Member of Scientific Advisory Board
- Dr. Kevin Brodbeck Ph.D.Chief Technical Officer
- Dr. Lori Sickels Friedman Ph.D.Chief Scientific Officer · born 1965
- Dr. Christian V. Kuhlen Esq., J.D., M.D.General Counsel & Chief Compliance Officer · born 1973
- Mr. Daniel IazzettiVP & Head of People